PRLD 8-K 2026-09-10
Prelude Therapeutics Inc (PRLD) 8-K dated 2026-09-10 — accession 0001193125-26-387232.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Prelude Therapeutics Inc filed a 8-K on 2026-09-10. Accession 0001193125-26-387232.
This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported PRLD revenue for 2025-12-31 was $12.1M. Net income was -$99.5M. Revenue was up 73.4% from 2024-12-31 to 2025-12-31. PRLD currently screens at market cap $346.5M.
Not investment advice. The PRLD SEC hub lists recent forms. The stock page is the research view.